1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Association, 2013.
Google Scholar | Crossref2. James, SL, Abate, D, Abate, KH, et al Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–1858.
Google Scholar | Crossref | Medline3. Bystritsky, A. Treatment-resistant anxiety disorders. Mol Psychiatry 2006; 11: 805–814.
Google Scholar | Crossref | Medline4. Roy-Byrne, P. Treatment-refractory anxiety; definition, risk factors, and treatment challenges. Dialogues Clin Neurosci 2015; 17: 191–206.
Google Scholar | Crossref | Medline5. Berman, RM, Cappiello, A, Anand, A, et al Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351–354.
Google Scholar | Crossref | Medline | ISI6. Diazgranados, N, Ibrahim, L, Brutsche, NE, et al A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793–802.
Google Scholar | Crossref | Medline7. Marcantoni, WS, Akoumba, BS, Wassef, M, et al A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009–January 2019. J Affect Dis 2000; 277: 831–841.
Google Scholar | Crossref8. McIntyre, RS, Rosenblat, JD, Nemeroff, CB, et al Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry 2021; 178: 383–399.
Google Scholar | Crossref | Medline9. Newport, DJ, Carpenter, LL, McDonald, WM, et al Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172: 950–966.
Google Scholar | Crossref | Medline | ISI10. Xu, Y, Hackett, M, Carter, G, et al Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2016; 19: pyv124.
Google Scholar | Crossref | ISI11. Kim, J, Farchione, T, Potter, A, et al Esketamine for treatment-resistant depression – first FDA-approved antidepressant in a new class. N Engl J Med 2019; 381: 1–4.
Google Scholar | Crossref | Medline12. Bruce, SE, Yonkers, KA, Otto, MW, et al Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005; 162: 1179–1187.
Google Scholar | Crossref | Medline | ISI13. Bokma, WA, Wetzer, GA, Gehrels, JB, et al Aligning the many definitions of treatment resistance in anxiety disorders: a systematic review. Depress Anxiety 2019; 36: 801–812.
Google Scholar | Crossref | Medline14. Banov, MD, Young, JR, Dunn, T, et al Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. CNS Spectr 2020; 25: 331–342.
Google Scholar | Crossref | Medline15. Davis, M, Myers, KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry 2002; 52: 998–1007.
Google Scholar | Crossref | Medline | ISI16. Kormos, V, Gaszner, B. Role of neuropeptides in anxiety, stress, and depression: from animals to humans. Neuropeptides 2013; 47: 401–419.
Google Scholar | Crossref | Medline17. McEwen, BS, Eiland, L, Hunter, RG, et al Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. Neuropharmacology 2012; 62: 3–12.
Google Scholar | Crossref | Medline | ISI18. Mion, G, Villevieille, T. Ketamine pharmacology: an update. CNS Neurosci Ther 2013; 19: 370–380.
Google Scholar | Crossref | Medline | ISI19. Zanos, P, Moaddel, R, Morris, PJ, et al Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 2018; 70: 621–660.
Google Scholar | Crossref | Medline20. Review Manager (RevMan) , version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Google Scholar21. Glue, P, Neehoff, S, Sabadel, A, et al Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. J Psychopharmacol 2020; 34: 267–272.
Google Scholar | SAGE Journals | ISI22. Taylor, JH, Landeros-Weisenberger, A, Coughlin, C, et al Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology 2018; 43: 325–333.
Google Scholar | Crossref | Medline23. Dadabayev, AR, Joshi, SA, Reda, MH, et al Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a randomized double-blind clinical trial. Chronic Stress 2020; 4: 2470547020981670.
Google Scholar | SAGE Journals24. Feder, A, Parides, MK, Murrough, JW, et al Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71: 681–688.
Google Scholar | Crossref | Medline | ISI25. Pradhan, B, Wainer, I, Moaddel, R, et al Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial. Asia Pac J Clin Trials Nerv Syst Dis 2017; 2: 80–90.
Google Scholar26. Rodriguez, CI, Kegeles, LS, Levinson, A, et al Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 2013; 38: 2475–2483.
Google Scholar | Crossref | Medline | ISI27. Marks, IM, Mathews, AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17: 263–267.
Google Scholar | Crossref | Medline | ISI28. Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55.
Google Scholar | Crossref | Medline | ISI29. Liebowitz, M. Social phobia. Mod Probl Pharmacopsychiatry 1987; 22: 141–173.
Google Scholar | Crossref | Medline30. Weiss, DS, Marmar, CR. The Impact of Event Scale–Revised. In: Wilson, J, Keane, TM (eds) Assessing psychological trauma and PTSD. New York: Guilford Press, 1996, pp. 399–411.
Google Scholar31. Weathers, FW, Keane, TM, Davidson, JR. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 2001; 13: 132–156.
Google Scholar | Crossref | Medline | ISI32. Weathers, F, Litz, B, Herman, D, et al The PTSD Checklist-civilian version (PCL-C). Boston, MA: National Center for PTSD, 1994.
Google Scholar33. Goodman, WK, Price, LH, Rasmussen, SA, et al The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006–1011.
Google Scholar | Crossref | Medline34. Rodriguez, CI, Kegeles, LS, Flood, P, et al Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011; 72: 567–569.
Google Scholar | Crossref | Medline35. Bremner, JD, Krystal, JH, Putnam, FW, et al Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). J Trauma Stress 1998; 11: 125–136.
Google Scholar | Crossref | Medline | ISI36. Truppman Lattie, D, Nehoff, H, Neehoff, S, et al Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. J Psychopharmacol 2021; 35: 137–141.
Google Scholar | SAGE Journals | ISI37. Spielberger, CD, Gorsuch, RL, Lushene, R, et al Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto, CA: Consulting Psychologist Press, 1983.
Google Scholar38. Glue, P, Neehoff, SM, Medlicott, NJ, et al Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalized anxiety and social anxiety disorders. J Psychopharmacol 2018; 32: 663–667.
Google Scholar | SAGE Journals | ISI39. Glue, P, Medlicott, NJ, Harland, S, et al Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol 2017; 31: 1302–1305.
Google Scholar | SAGE Journals | ISI40. Fava, M, Freeman, MP, Flynn, M, et al Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry 2020; 25: 1592–1603.
Google Scholar | Crossref | Medline41. Feder, A, Costi, S, Rutter, SB, et al A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 2021; 178: 193–202.
Google Scholar | Crossref | Medline42. Phillips, JL, Norris, S, Talbot, J, et al Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry 2020; 176: 401–409.
Google Scholar | Crossref43. Sanacora, G, Frye, MA, McDonald, W, et al A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017; 74: 399–405.
Google Scholar | Crossref | Medline